iiinova — where your digital self keeps evolving

Paul Bonanos

@biobonanos.bsky.social

517 followers 93 following 462 posts

I write some, I edit some

Posts Replies Media

Paul Bonanos @biobonanos.bsky.social · 30/05/2026

Leaders of U.S. drug companies should use their influence to stop a ruinous proposal, argues @steveusdin.bsky.social in a BioCentury commentary.

Pharma CEO silence is complicity in the destruction of U.S. science

Office of Management and Budget Director Russell Vought has poured gas on the foundations of science. Pharma CEOs should demand that President Donald Trump...

Paul Bonanos @biobonanos.bsky.social · 17/03/2026

I spoke with co-founder Krishna Polu about the launch of R1 Therapeutics. The start-up has obtained most global rights to a therapy from China-based Alebund that inhibits phosphate transporters in the intestine to treat a common complication of kidney disease: www.biocentury.com/article/6587...

R1: China-to-U.S. NewCo planning global testing of new CKD mechanism

California-based R1 is using the NewCo model to fund global clinical testing of a molecule with first-in-class potential to treat hyperphosphatemia associa...

Paul Bonanos @biobonanos.bsky.social · 18/02/2026

FDA's CBER will review Moderna's mRNA-1010 flu vaccine after all.... www.accessnewswire.com/newsroom/en/...

accessnewswire.com

Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

ACCESS Newswire provides PR agencies with trusted press release distribution, media outreach tools, media lists, pitching features, analytics, monitoring, and dedicated support designed for multi-clie...

Paul Bonanos @biobonanos.bsky.social · 29/01/2026

My BioCentury colleague Lauren Martz looks ahead to a big year of catalysts, with innovations in RNA-targeting therapies leading the way. www.biocentury.com/article/6581...

In an analysis of the most highly anticipated clinical and regulatory milestones of 2026, RNA-targeting therapies are everywhere. Antisense and siRNA programs are transitioning from new to established modalities, with 2026 bringing a slate of catalysts ranging from proof-of-concept readouts in new disease spaces to regulatory decisions in large-market indications.

As RNAi and other RNA-targeting drugs advance, they’re also helping define the clinical, regulatory and commercial playbook for other new modalities.

One defining event will be data from the Phase III HORIZON study of pelacarsen, an Lp(a)-targeting antisense oligo from partners Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Novartis AG (SIX:NOVN; NYSE:NVS). But pelacarsen is just one of about 20 RNAi therapies with pivotal data and regulatory catalysts highlighted by BioCentury this year.

Paul Bonanos @biobonanos.bsky.social · 20/01/2026

Rapt Therapeutics has steered into a $2.2b acquisition by GSK, which appears most interested in developing the biotech's IgE-targeting Xolair competitor for a prophylactic food allergy indication. www.gsk.com/en-gb/media/...

GSK enters agreement to acquire RAPT Therapeutics | GSK

Acquisition adds to Respiratory, Immunology & Inflammation pipeline

Paul Bonanos @biobonanos.bsky.social · 10/12/2025

Eight public biotechs raised a total of >$3.2 billion overnight. Most had strong data readouts in the past few days. All but one upsized their offerings from their proposed targets. They say a healthy follow-on market augurs a healthy IPO market. $GPCR $WVE $DYN $VERA $FULC $KYMR $TERN $DNLI

Reposted by Paul Bonanos

Craig M. Crews @craigmcrews.bsky.social · 17/11/2025

Great news for Halda Therapeutics and for prostate cancer patients! HLD-0915 has great potential to help those with metastatic castration resistant prostate cancer, who have failed prior therapies. #Halda #prostatecancer www.jnj.com/media-center...

Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics

Acquisition provides highly differentiated clinical-stage treatment for prostate cancer, building on Johnson & Johnson’s nearly two decades of innovation in the disease area Lead asset shows potential...

Paul Bonanos @biobonanos.bsky.social · 24/10/2025

Biogen is in-licensing Vanqua's C5aR1 program for $70m up front, plus $990m in potential milestones. It's an oral small molecule that complements a mAb in BIIB's pipeline, obtained via its HI-Bio acquisition. Two shots at a pipeline-in-a-product to treat inflammatory diseases.

globenewswire.com

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE,...

000

Paul Bonanos @biobonanos.bsky.social · 23/10/2025

Ventyx Biosciences' shares are set to double (+100% premarket) following a readout for its CNS-penetrant NLRP3 inhibitor in patients with obesity and CV risk factors: www.globenewswire.com/news-release... My colleague @stephenhansen.bsky.social wrote about the mechanism last year. Story below.

Treating obesity by quelling inflammation in the brain

Preclinical data suggest NLRP3 could be an important new target for treating obesity. Among the benefits could be oral dosing with fewer side effects than ...

000

Paul Bonanos @biobonanos.bsky.social · 22/10/2025

A deal with Takeda could prove transformative for China-based Innovent Biologics as the partners seek to co-commercialize a bispecific oncology therapy in the U.S. Two other therapies are part of the deal as well; a $1.2 billion upfront component could turn into $11.4 billion in total payments.

With Takeda deal, Innovent takes giant step toward global innovation

Innovent has long sought to evolve from an oncology leader in China to a global innovator. A deal with Takeda on Wednesday around three products represents...

Paul Bonanos @biobonanos.bsky.social · 09/10/2025

FGF21 agonist M&A: May 2025: GSK pays $1.2b upfront for Boston Pharma's efimosferin; deal includes $800m in milestones Sept. 2025: Roche buys 89bio for $2.4b upfront, gaining pegozafermin; $1b CVR Today: Novo buys Akero for $4.7b upfront, adding efruxifermin; ~$500m CVR

globenewswire.com

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet...

Paul Bonanos @biobonanos.bsky.social · 07/10/2025

Months after RFK Jr and Marty Makary pushed Peter Marks out of FDA, the former CBER director has taken an SVP role at Lilly. @steveusdin.bsky.social has the scoop in @biocentury.bsky.social.

Former CBER Director Marks joins Lilly

Peter Marks has joined Eli Lilly and Co. (NYSE:LLY) as SVP for molecule discovery and head of infectious diseases, marking his return to industry after ne...

Paul Bonanos @biobonanos.bsky.social · 06/10/2025

TCG X's Chen Yu has reasons to be optimistic during a difficult cycle for biotech investors. I spoke with him about the firm's newly disclosed $1.3 billion third fund, its largest yet. Story: www.biocentury.com/article/6571...

Seeing opportunities among headwinds, TCG X closes $1.3B third fund

Despite headwinds facing the biotech industry, TCG Crossover’s Chen Yu believes the firm will deploy its new $1.3 billion fund during “a...

Paul Bonanos @biobonanos.bsky.social · 22/09/2025

Lazard's annual biopharma survey is out this morning. I spoke with the firm's David Gluckman about the risks and challenges the industry faces -- and some reasons to be optimistic. Story (no paywall): www.biocentury.com/article/6570...

Lazard survey: Large caps could consolidate as biopharmas face variety of pressures

Executives and investors surveyed by Lazard increasingly believe consolidation among large-cap biopharmas is likely, while industry leaders see U.S. admini...

000

Paul Bonanos @biobonanos.bsky.social · 03/09/2025

Our story in @biocentury.bsky.social, by @steveusdin.bsky.social.

Paul Bonanos @biobonanos.bsky.social · 02/09/2025

I spoke with @jmaraganore.bsky.social and Clive Meanwell about their new company, Corsera Health. They're seeking to apply the disease interception model to CV health -- identifying risk at an early age and stopping disease from developing in at-risk people. My story:

Corsera: Maraganore, Meanwell bring the disease interception model to CV risk

Rooted in the belief that some cases of cardiovascular disease can be forestalled by identifying risk at an early age, a start-up led by biotech veterans J...

000

Paul Bonanos @biobonanos.bsky.social · 22/08/2025

What to make of FDA's about-face on Stealth BioTherapeutics' therapy for Barth syndrome? Denied CRL appeal, then signaled it would conduct an unusually quick review -- with a decision due just five weeks after resubmission. Pressure from patient advocates seems to be a factor. Story:

FDA’s about-face on Stealth a positive sign for rare disease therapies?

Following FDA’s denial of a request to reconsider a complete response letter, the agency is now promising an unusually quick review for St...

Paul Bonanos @biobonanos.bsky.social · 15/08/2025

FDA granted full approval to a treatment for a rare disease based on a single-arm study of 35 evaluable patients, even though its sponsor was seeking accelerated approval. No confirmatory trial needed. And this, from CBER director Vinay Prasad, seems like a signal: www.fda.gov/news-events/...

From FDA's release:

“Randomized trials are not always needed to approve medical products and this approval is proof of that philosophy,” said Vinay Prasad, M.D., M.P.H., Director of the FDA’s Center for Biologics Evaluation and Research (CBER). “The FDA will always demand the correct clinical study for the specific medical product and disease. Our requirements for products given to tens of millions of healthy people will be different than products given to at most hundreds or thousands of patients with unique diseases.”

Paul Bonanos @biobonanos.bsky.social · 11/08/2025

VC-backed Expedition Therapeutics, set up to in-license assets from China and develop them in the West, has struck a deal with Fosun for a clinical DPP-1 inhibitor to treat inflammatory and respiratory indications. $17m up front, $628m in milestones. Read about it in BioCentury's Deals Report 👇

Expedition picks Fosun therapy for first China in-licensing agreement: Deals Report

A start-up hunting for in-licensing opportunities in China has closed its first deal, gaining most global rights to a program from Fosun.Backed by Venrock,...

Paul Bonanos @biobonanos.bsky.social · 22/07/2025

ICYMI (overnight in many geographies) -- Sanofi is paying $1.15b up front to acquire venture-backed vaccine company Vicebio. Early clinical data were the deal's trigger, chairman Giovanni Mariggi of founding investor Medicxi tells me. Story: www.biocentury.com/article/6565...

First clinical evidence spurs Sanofi’s takeout of Vicebio for $1.15B up front

Early data emerging from a clinical study of the first product derived from Vicebio’s vaccine platform have spurred Sanofi’s decision to acqu...

Paul Bonanos @biobonanos.bsky.social · 09/07/2025

Good morning #biosky! Merck/MSD is paying $10b to acquire Verona Pharma, obtaining an approved PDE3/PDE4 dual inhibitor for COPD. $107/share price is a 23% premium over Tuesday's close. www.merck.com/news/merck-t...

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade -...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Merck to hold investor call at 8 a.m. ET today ...

Reposted by Paul Bonanos

Joshua J. Friedman @joshuajfriedman.com · 07/07/2025

READ THE COMPLAINT: storage.courtlistener.com/recap/gov.us...

INTRODUCTION
On May 27, 2025, Defendant, the Secretary of the United States Department of
Health and Human Services, Robert F. Kennedy, Jr. (the "Secretary" or "Mr. Kennedy"), announced in a post on social media site X that he "couldn't be more pleased that, as of today, the Covid vaccine
for healthy children and healthy pregnant women has been removed from the CDC recommended
immunization schedules."! Unless the Secretary's baseless and uninformed policy decision is vacated, pregnant women, their unborn children, and, in fact, all children remain at grave and immediate risk of contracting a preventable disease. This decision immediately exposes these
vulnerable populations to a serious illness with potentially irreversible long-term effects and, in
some cases, death. This is not a hypothetical concern, but a pressing public health emergency that
demands immediate legal action and correction.

Paul Bonanos @biobonanos.bsky.social · 11/06/2025

SpliceBio's new round is the largest ever -- by a lot -- for a Spain-based biotech, according to BioCentury's BCIQ database. We've been watching the life sciences ecosystem grow in Spain for some time, and early SpliceBio investor Ysios has been a major driver: www.biocentury.com/article/6410...

Paul Bonanos @biobonanos.bsky.social · 29/05/2025

Intellia NTLA is -28% just after the morning bell. The biotech disclosed a case of liver toxicity in its Phase 3 amyloidosis study, here in an 8-K and apparently on a private call with analysts last evening: www.sec.gov/ix?doc=/Arch...

Paul Bonanos @biobonanos.bsky.social · 29/05/2025

Here's a $60m series A for Vima, a newly launched company "with a singular focus: to change the lives of patients with dystonia." That's from co-founder/chairman David Grayzel of Atlas Venture, which led the round. Release here, management team in screenshot: www.globenewswire.com/news-release...

Vima’s executive officers:

Bernard Ravina, MD, MS, founder and chief executive officer, has over 25 years of drug development experience in government, academia, and industry, and was a practicing neurologist specializing in movement disorders. He has served in leadership positions at Biogen, Voyager Therapeutics, and Praxis Medicines.

Judith Dunn, PhD, president and head of R&D, has 30+ years of drug development experience and has held leadership roles in biotech and pharma, including global head of clinical development at Roche.

Jessica Fees, chief financial officer, brings over 20 years of finance and strategic leadership experience in the biotech industry. Prior to Vima, she served as chief financial officer at Surface Oncology.

Ariel D. Jasie, JD, chief business officer and general counsel, has over 20 years of industry experience and has served as chief business officer and general counsel to multiple private biotech companies.

Tushar Misra, PhD, chief technical officer, has been in the pharmaceutical industry for over 30 years and has worked across the entire value chain from R&D to Commercialization, with leadership roles at many companies, including Wyeth, Sepracor, and Takeda.

Paul Bonanos @biobonanos.bsky.social · 29/05/2025

We had noted the slowdown in follow-on activity amid high volatility this year, with no substantial NASDAQ offerings at all by biotechs during April. The overnight offering from Taysha ($200m last evening), looks like the biggest by a biotech since March. Story: www.biocentury.com/article/6558...

No follow-ons in April as drought crosses five-week threshold: Finance Report

For the first time in at least six years, public life sciences companies disclosed zero follow-on fundings of $25 million or more in a calendar month,...

Paul Bonanos @biobonanos.bsky.social · 29/05/2025

RBL, the venture studio formed last year with ties to Rice University and KdT Ventures, has just introduced its first biotech spinout. Sentinel BioTherapeutics will present Phase I data at ASCO for its IL-2 program for immuno-oncology. Our October story on RBL: www.biocentury.com/article/6539...

Why Rice is launching a venture studio in Houston’s emerging biotech ecosystem

The founders of Rice University’s new venture studio believe they can incubate and launch multiple new biotechs each year, capitalizing on a maturi...

Paul Bonanos @biobonanos.bsky.social · 27/05/2025

A patient has passed away in Rocket Pharma’s Phase II study of its gene therapy for Danon disease. The study is under clinical hold and Rocket is evaluating next steps. ir.rocketpharma.com/news-release...

Paul Bonanos @biobonanos.bsky.social · 27/05/2025

Good morning #biosky! Today Biogen is paying City Therapeutics $46m up front, including a $30m equity investment, to develop RNAi medicines, starting with a CNS target. $1b biobucks + royalties. Release: www.globenewswire.com/news-release...

globenewswire.com

Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies

Collaboration leverages City Therapeutics’ next-generation RNAi engineering technologies and Biogen’s extensive drug development expertise...

Reposted by Paul Bonanos

Gregory Koblentz @gregkoblentz.bsky.social · 21/05/2025

That giant sucking sound you hear is 80 years of US investment in soft power going down the drain China to donate $500 million to WHO, stepping into gap left by U.S. www.washingtonpost.com/world/2025/0...

washingtonpost.com

China to donate $500 million to WHO, stepping into gap left by U.S.

Beijing will replace the United States as the organization’s top state donor, expanding its influence as the U.S. retreats from international cooperation.

Paul Bonanos @biobonanos.bsky.social · 16/05/2025

BioMarin is buying Inozyme for $4/share, or $270m; it's a 182% premium over Thursday's close of $1.42. Data are due in early 2026 from a Phase III study of $INZY's enzyme replacement therapy for ENPP1 deficiency. Release:

investors.biomarin.com

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Therapy Being Developed for Treatment of ENPP1 Deficiency First Pivotal Data Readout in Children Expected...

Paul Bonanos @biobonanos.bsky.social · 14/05/2025

GSK is buying Boston Pharma’s lead asset, an FGF21 agonist for liver disease, for $1.2B up front + $800m milestones. The former Novartis molecule drives a strong return for Boston backer Gurnet Point. Release: www.gsk.com/en-gb/media/... A little background: www.biocentury.com/article/6462...

Kornowski shifts gears at Boston Pharma, sets NASH program as top priority

Seven years after Gurnet Point launched Boston Pharma, new CEO Sophie Kornowski is leading a transition away from the company’s prior model of bring...

Paul Bonanos @biobonanos.bsky.social · 12/05/2025

An anecdote describing the death of English novelist Arnold Bennett, who was convinced that Parisian tap water was safe to drink. Before and after a dinner with James and Nora Joyce, Bennett drank the tap water twice. He contracted typhoid and died a few weeks later.

000

Reposted by Paul Bonanos

Scott Gottlieb, MD @scottgottliebmd.bsky.social · 06/05/2025

My op-ed on the large shift of drug discovery moving to China and policy steps the U.S. can take to keep the innovation economy in America. "Five years ago, U.S. drug makers didn’t license any new drugs from China. By 2024, one-third came from Chinese biotech"

How to stop the shift of drug discovery from the U.S. to China

U.S. pharmaceutical companies are increasingly licensing new drugs from China. Former FDA Commissioner Scott Gottlieb explains how to stop the shift.

Paul Bonanos @biobonanos.bsky.social · 01/05/2025

The latest biotech to accept a buyout from Tang Capital-backed Concentra: It's Kronos Bio, the company that was until recently led by Norbert Bischofberger. CDK9 discontinued in November; laid off most staff. $112m cash at Dec. 31; complex CVR.

globenewswire.com

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (

000

Paul Bonanos @biobonanos.bsky.social · 30/04/2025

Novartis promised more "value-creating bolt-ons" during yesterday's conference call. Today, the pharma is buying Regulus Therapeutics for $7/share ("$0.8 billion"), with a CVR that could double the price to $1.7b. Regulus' anti-miR oligo for ADPKD is in Phase 1b.

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

/PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines...

Reposted by Paul Bonanos

steveusdin.bsky.social @steveusdin.bsky.social · 29/04/2025

FDA misses PDUFA goal for Stealth’s Barth syndrome treatment It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy. www.biocentury.com/article/655776

FDA misses PDUFA goal for Stealth’s Barth syndrome treatment

FDA has missed another PDUFA review deadline, this time for a treatment that a small biotech is developing for an ultrarare disease. Stealth Biotherapeutic...

Paul Bonanos @biobonanos.bsky.social · 28/04/2025

A few words on this morning's Merck KGaA/SpringWorks deal: Two rare tumor treatments, a takeout consummated after months of rumors, and relief from an M&A drought: www.biocentury.com/article/6557...

Eight-year-run for Pfizer spinout Springworks culminates in Merck KGaA buyout

The takeout of Springworks by Merck KGaA will fortify the German company’s oncology business with a pair of approved drugs for rare tumors, while al...

Reposted by Paul Bonanos

Scott Gottlieb, MD @scottgottliebmd.bsky.social · 25/04/2025

Steve Usdin writing in BioCentury: “It’s official: FDA says its cuts are delaying drug regulation — Layoffs, lack of access to journals slow response FDA says”

Paul Bonanos @biobonanos.bsky.social · 21/04/2025

Two key management moves at Galapagos: - CEO Paul Stoffels (ex-JNJ CSO) is retiring this year, but will remain chairman - Ex-Neumora CEO Henry Gosebruch will be CEO of the planned GLPG spinout Release: www.globenewswire.com/news-release... Background ($): www.biocentury.com/article/6546...

Makeover for Gilead-Galapagos deal to yield newco primed for BD

What has become of Galapagos a little more than five years after its major partnership with Gilead is far from what the partners had envisioned for the meg...

Paul Bonanos @biobonanos.bsky.social · 17/04/2025

If LLY's +11% premarket stock move holds, it'd gain about $75 billion in market cap. New oral GLP-1 data in diabetic patients is the driver: www.prnewswire.com/news-release...

100

Paul Bonanos @biobonanos.bsky.social · 17/04/2025

I hadn't heard of Earendil Labs -- this may be its first announcement, datelined Middletown, Delaware -- but it's receiving $125m up front from Sanofi for rights to two bispecifics (α4β7xTL1A, TL1AxIL23) for IBD/autoimmune disease. $1.72b biobucks, plus royalties. www.prnewswire.com/news-release...

Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases

/PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that...

Reposted by Paul Bonanos

steveusdin.bsky.social @steveusdin.bsky.social · 10/04/2025

RFK Jr cited pseudo-science to justify holding up of Novavax COVID vaccine. He said single-antigen vaccines don’t protect against respiratory diseases. There are 2 FDA-approved sgl antigen vaccines for RSV. And data on Novavax solid, FDA reviewers said. www.biocentury.com/article/655591

Paul Bonanos @biobonanos.bsky.social · 03/04/2025

More competition in the IgA nephropathy arena as Novartis wins accelerated approval of Vanrafia atrasentan. No REMS, apparently satisfying a $2/share CVR tied to Novartis' 2023 acquisition of Chinook. www.prnewswire.com/news-release...

Language from a regulatory filing, when Novartis acquired Chinook:

Contingent Value Rights Agreement

At or immediately prior to the Effective Time, Novartis and a rights agent will enter into the CVR Agreement, governing the terms of the CVRs to be received by the Company’s stockholders. The CVRs are not transferable except under certain limited circumstances, will not be evidenced by a certificate or other instrument and will not be registered or listed for trading. The CVRs will not have any voting or dividend rights and will not represent any equity or ownership interest in Novartis, Merger Sub, the Company or any of their affiliates.

Each CVR represents the right to receive the following contingent cash payments:

•
$2.00 if the U.S Food and Drug Administration (the “FDA”) approves a new drug application for atrasentan for the treatment of Immunoglobulin A nephropathy, which approval does not impose a risk evaluation and mitigation strategy that is related to liver toxicity, on or before December 31, 2025; and

•
$2.00 if the FDA approves a new drug application for atrasentan for the treatment of focal segmental glomerulosclerosis on or before December 31, 2029.

There can be no assurance that the milestones will be achieved during relevant periods, and that the resulting milestone payments will occur.

The foregoing description of the CVR Agreement is not complete and is qualified in its entirety by reference to the Form of CVR Agreement, which is attached as Exhibit A to the Merger Agreement in Exhibit 2.1, and is incorporated herein by reference.

000

Paul Bonanos @biobonanos.bsky.social · 01/04/2025

I'm hearing from @steveusdin.bsky.social that another key official has been forced out from FDA. Peter Stein, longtime director of CDER’s Office of New Drugs, faced demotion and resigned. BioCentury story coming today.

Paul Bonanos @biobonanos.bsky.social · 28/03/2025

Novo is paying Lexicon $75m up front for rights to an oral therapy targeting ACSL5 to treat obesity; the non-incretin treatment is still preclinical. www.globenewswire.com/news-release...

globenewswire.com

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and...

Paul Bonanos @biobonanos.bsky.social · 25/03/2025

Good morning #biosky! Merck is paying $200m for ex-Greater China rights to an Lp(a) program from Jiangsu Hengrui, now in Phase 2 testing in China. Deal includes $1.77m in biobucks. Recall: AZ paid CSPC $100m in October for rights to an Lp(a) disruptor. www.businesswire.com/news/home/20....

Paul Bonanos @biobonanos.bsky.social · 20/03/2025

A few words on Amvuttra's label expansion this evening to include the larger ATTR indication with cardiomyopathy -- helping Alnylam fulfill its ambition to reach profitability this year: www.biocentury.com/article/6554...

Amvuttra’s label expansion lifts Alnylam toward five-year goals

FDA’s expansion Thursday of Amvuttra’s label to include amyloidosis patients with cardiomyopathy should position Alnylam to satisfy most of t...

Paul Bonanos @biobonanos.bsky.social · 18/03/2025

I had a word with Sofinnova's Graziano Seghezzi about how the firm will deploy €165m to back companies in what is now the largest biotech accelerator in Europe: www.biocentury.com/article/6553...

Strategics back Sofinnova Partners’ ‘pan-European’ accelerator in €165M fund

European venture firm Sofinnova Partners has closed a new fund dedicated to supporting companies moving through its Biovelocita accelerator, a strategy it ...

Paul Bonanos @biobonanos.bsky.social · 17/03/2025

Curevo will put a new $110m round toward development of its Shringrix competitor, which it believes has tolerability advantages over the incumbent shingles vaccine. I spoke with the company, new board member Moncef Slaoui (ex-GSK) and lead investor Medicxi. Story: www.biocentury.com/article/6553...

With Medicxi’s backing, Curevo takes aim at Shingrix with $110M series B

With a new $110 million series B led by Medicxi, Seattle-based Curevo is moving a potential competitor to blockbuster shingles vaccine Shingrix toward...